Literature DB >> 16171436

Amelogenin stimulates bone sialoprotein (BSP) expression through fibroblast growth factor 2 response element and transforming growth factor-beta1 activation element in the promoter of the BSP gene.

Emi Shimizu1, Ryoichiro Saito, Youhei Nakayama, Yu Nakajima, Naoko Kato, Hideki Takai, Dong-Soon Kim, Masato Arai, James Simmer, Yorimasa Ogata.   

Abstract

BACKGROUND: Amelogenins are a complex mixture of hydrophobic proteins that are the major organic component of developing enamel. The principal function of the amelogenins and their degradation products has been assigned to structural roles in creating the space and milieu for promoting enamel mineralization. Enamel matrix derivative (EMD) has been used clinically for periodontal regeneration and its therapeutic effectiveness has been attributed to amelogenin, non-amelogenin enamel matrix proteins, and growth factors. While EMD is believed to induce periodontal regeneration, the precise mechanism is not known. Bone sialoprotein (BSP), an early phenotypic marker of osteoblast and cementoblast differentiation, has been implicated in the nucleation of hydroxyapatite during bone formation. In this study, we examined the ability of amelogenin to regulate BSP gene transcription in osteoblast like cells.
METHODS: We conducted Northern hybridization, transient transfection analyses, and gel mobility shift assays using full-length recombinant amelogenin to determine the molecular basis of the transcriptional regulation of BSP gene by amelogenin.
RESULTS: Recombinant amelogenin (1 microg/ml, 12 hours) increased BSP mRNA levels approximately 2.4-fold. In transient transfection analyses, amelogenin (1 microg/ml, 12 hours) increased luciferase activity approximately 1.5-fold in pLUC3 (nucleotides -116 to +60) and further increased pLUC5 (nucleotides -801 to +60) activity approximately 2.3-fold transfected into ROS 17/2.8 cells. Amelogenin also increased luciferase activities in rat stromal bone marrow cells. The effect of amelogenin was inhibited by the tyrosine kinase inhibitor herbimycin A. Transcriptional stimulation by amelogenin was almost completely abrogated in cells expressing a BSP promoter construct with a mutation in the fibroblast growth factor 2 (FGF2) response element (FRE). Gel mobility shift assays with radiolabeled FRE and transforming growth factor-beta1 (TGF-beta1) activation element (TAE) ds-oligonucleotides revealed increased binding of nuclear proteins from amelogenin-stimulated ROS 17/2.8 cells.
CONCLUSION: Amelogenin stimulation alters BSP gene transcription by inducing nuclear proteins that bind to the FRE and TAE in the rat BSP gene promoter.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16171436     DOI: 10.1902/jop.2005.76.9.1482

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  6 in total

1.  Rescue of the murine amelogenin null phenotype with two amelogenin transgenes.

Authors:  Carolyn W Gibson; Yong Li; Cynthia Suggs; Melissa A Kuehl; Megan K Pugach; Ashok B Kulkarni; John T Wright
Journal:  Eur J Oral Sci       Date:  2011-12       Impact factor: 2.612

2.  Effects of enamel matrix proteins on proliferation, differentiation and attachment of human alveolar osteoblasts.

Authors:  S-Y Jiang; R Shu; Z-C Song; Y-F Xie
Journal:  Cell Prolif       Date:  2011-08       Impact factor: 6.831

Review 3.  Enamel matrix proteins; old molecules for new applications.

Authors:  S P Lyngstadaas; J C Wohlfahrt; S J Brookes; M L Paine; M L Snead; J E Reseland
Journal:  Orthod Craniofac Res       Date:  2009-08       Impact factor: 1.826

4.  Premature osteoblast clustering by enamel matrix proteins induces osteoblast differentiation through up-regulation of connexin 43 and N-cadherin.

Authors:  Richard J Miron; Erik Hedbom; Sabrina Ruggiero; Dieter D Bosshardt; Yufeng Zhang; Corinna Mauth; Anja C Gemperli; Tateyuki Iizuka; Daniel Buser; Anton Sculean
Journal:  PLoS One       Date:  2011-08-15       Impact factor: 3.240

5.  Leucine rich amelogenin peptide prevents ovariectomy-induced bone loss in mice.

Authors:  Naoto Haruyama; Takayoshi Yamaza; Shigeki Suzuki; Bradford Hall; Andrew Cho; Carolyn W Gibson; Ashok B Kulkarni
Journal:  PLoS One       Date:  2021-11-15       Impact factor: 3.240

6.  Controlled Osteogenic Differentiation of Mouse Mesenchymal Stem Cells by Tetracycline-Controlled Transcriptional Activation of Amelogenin.

Authors:  Fangfang Wang; Hiroko Okawa; Yuya Kamano; Kunimichi Niibe; Hiroki Kayashima; Thanaphum Osathanon; Prasit Pavasant; Makio Saeki; Hirofumi Yatani; Hiroshi Egusa
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.